NEW YORK, NY / ACCESSWIRE / November 30, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
HPQ Shareholders Click Here: https://www.zlk.com/pslra-1/hp-inc-loss-submission-form?prid=11262&wire=1
BIIB Shareholders Click Here: https://www.zlk.com/pslra-1/biogen-inc-loss-submission-form?prid=11262&wire=1
BABA Shareholders Click Here: https://www.zlk.com/pslra-1/alibaba-group-holding-limited-loss-submission-form?prid=11262&wire=1
* ADDITIONAL INFORMATION BELOW *
HP Inc. (NYSE: HPQ)
HPQ Lawsuit on behalf of: investors who purchased November 6, 2015 - June 21, 2016
Lead Plaintiff Deadline : January 4, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/hp-inc-loss-submission-form?prid=11262&wire=1
According to the filed complaint, during the class period, HP Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) HP's channel inventory management and sales practices resulted in the sale of supplies to customers that did not need or want the product in order to artificially increase revenues and profits; (b) HP's channel inventory management and sales practices resulted in the sale of supplies to customers outside of designated regions at unsustainable discounts in order to artificially increase revenues and profits; (c) HP's channel inventory management and sales practices resulted in the sale of supplies at steep discounts to customers to encourage those customers to sell the supplies further down the supply channel, out of HP's inventory management metrics; and (d) as a result of (a)-(c) above, defendants' statements about HP's business condition and prospects were materially false and misleading when made.
Biogen Inc. (NASDAQ: BIIB)
BIIB Lawsuit on behalf of: investors who purchased October 22, 2019 - November 6, 2019
Lead Plaintiff Deadline : January 12, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/biogen-inc-loss-submission-form?prid=11262&wire=1
According to the filed complaint, during the class period, Biogen Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab's effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding the effectiveness of aducanumab, Biogen's investigational human monoclonal antibody studied for the treatment of early Alzheimer's disease; (3) the PRIME study did not and would not provide necessary data regarding aducanumab's effectiveness; (4) the data provided by the Company to the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Alibaba Group Holding Limited (NYSE: BABA)
BABA Lawsuit on behalf of: investors who purchased October 21, 2020 - November 3, 2020
Lead Plaintiff Deadline : January 12, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/alibaba-group-holding-limited-loss-submission-form?prid=11262&wire=1
According to the filed complaint, during the class period, Alibaba Group Holding Limited made materially false and/or misleading statements and/or failed to disclose that: (1) Ant Small and Micro Financial Services Group Co., Ltd. ("Ant Group"), a financial technology company in which Alibaba owns a 33% equity interest, did not meet listing qualifications or disclosure requirements for certain material matters; (2) certain impending changes in the Fintech regulatory environment would impact Ant Group's business; (3) as a result of the foregoing, Ant Group's initial public offering was reasonably likely to be suspended; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP